Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan to sell brazikumab and Zenpep to close $63bn deal with AbbVie
Allergan has agreed to sell brazikumab (formerly MEDI2070) and Zenpep (pancrelipase) to AstraZeneca and Nestle, respectively, in separate deals, for an undisclosed price.
Production & Sales
-
28 Jan 2020
-
28 Jan 2020
Atnahs Pharma to buy AstraZeneca’s hypertension medicines in $390m deal
Atnahs Pharma has agreed to acquire hypertension medicines from AstraZeneca in a deal valued at around $390m.
-
22 Jan 2020
Calidi Biotherapeutics secures series A investments to advance manufacturing
Calidi Biotherapeutics, a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two South Korean firms to advance manufacturing in preparation for Calidi's pre-IND and IND filings.
-
22 Jan 2020
Eli Lilly to build $470m pharmaceutical manufacturing facility in North Carolina
Eli Lilly is set to invest more than $470m to build a new pharmaceutical manufacturing facility in North Carolina, US.
-
21 Jan 2020
Armas Pharmaceuticals adds four generic injectables as first launches of 2020
The products are now a part of Armas' consistently growing product line, bringing their portfolio count to eleven
-
14 Jan 2020
Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US
Bayer has entered into a licence agreement with Daré Bioscience to commercialise investigational contraceptive product called Ovaprene in the US.
-
06 Jan 2020
Charles River Laboratories wraps up $380m acquisition of HemaCare
Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.
-
03 Jan 2020
Amgen closes acquisition of 20.5% stake in BeiGene for $2.8bn
US-based Amgen has closed the acquisition of a 20.5% stake in Chinese biopharmaceutical firm BeiGene for approximately $2.8bn to support the expansion of its oncology footprint in China.
-
02 Jan 2020
GSK closes sale of two vaccine brands to Bavarian Nordic
GlaxoSmithKline (GSK) has completed the sale of its travel vaccines Rabipur for rabies, and Encepur for tick-borne encephalitis, to Bavarian Nordic.
-
17 Dec 2019
AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm).